Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 41,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Most Popular Stories
- DOD, VA move to SOA architecture to build interoperable systems
- UnitedHealth reveals details of option back-dating settlement
- Social Security wants EMR access for disability determination
- Study: EMRs can cut paid malpractice settlements
- Forum: IT won't help much until practices shift operations
- HHS: 60 percent of DME companies banned by Medicare may keep billing
Poll
Featured Jobs
-
Phamacy Auditor
Pharm/DUR, Inc. - Philadelphia, PA -
Tennessee Vascular/General Surgeon
StaffPointe, LLC - near Nashville , TN -
Texas Hospitalist
StaffPointe, LLC - south , TX -
Virginia PA or NP
StaffPointe, LLC - near Virginia Beach , VA -
Virginia Dialysis Registered Nurse
StaffPointe, LLC - north , VA
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
stents news from FierceHealthcare
News
Small hospitals may be safe to do angioplasties
Trend: Heart stent maker markets directly to patients
SPOTLIGHT: Stent problems change cardiology tactics
SPOTLIGHT: NEJM gives reviewer the boot
It looks like high-profile cardiologist Dr. Martin Leon has been booted from the New England Journal of Medicine peer review panel for five years. His offense? He allegedly leaked results from COURAGE, a high-profile study comparing stents with drug therapy in treating stable heart disease. Article
Insurers may cut stent payouts
A new study suggesting that stents don't help non-emergency cardiac patients more than drugs could soon change how insurers reimburse for such treatments, observers say. The recent New England Journal of Medicine study, which looked at 2,287 non-emergency patients, found that angioplasty and stenting didn't save lives or prevent heart attacks, though it did reduce chest pain. Right now, roughly 50 to 80 percent of angioplasties are performed on non-emergency patients, with …
... Read more...ALSO NOTED: Duke launches doctor-patient portal; Bypass surgery making a comeback?; and much more...
> The American Medical Group Association, which represents large practices like the Cleveland Clinic, wants to see the government help to pay for their growing investments in cutting edge technologies like EMRs. Report
> For the past decade, surgeons have been performing fewer heart bypasses, opting to treat patients using stents instead. But in light of recent stent safety …
... Read more...Number of cardiac surgery jobs falling
As the use of stents has grown and the number of cardiac bypass procedures has fallen in turn, jobs for cardiac surgeons have taken a hit. These days, cardiac surgeons who keep up active practices are often picking up a lot more heart valve or lung surgeries rather than focusing on bypass procedures. The dip in job opportunity is so pronounced that the specialty is falling out of favor in medical school. According to an article published in the Annals of Thoracic Surgery last …
... Read more...SPOTLIGHT: AHRQ goes podcasting
The HHS Agency for Healthcare Research and Quality has apparently gotten the iPod memo. The agency is now publishing a "Healthcare 411" podcast series, offering a mix of self-promotional and serious clinical content. The current broadcast focuses on the apparently decreased risk of death or heart attack from drug-coated stents when anti-clotting treatments are used for a longer period. Podcasts
SPOTLIGHT: When treatments don't work, whose problem is it?
When treatments don't work, whose problem is it?
At an FDA hearing last week, panel members soberly discussed the evidence as to whether drug-coated stents were responsible for an increased risk of future blood clots. Such safety reviews are obviously a good thing, but sometimes they sidestep other issues, says writer David Leonhardt. In this case, the FDA didn't even take on the issue of whether the stents--and preceding angioplasties--should be done in the first …
SPOTLIGHT: When standard procedures don't work
Evidence-based medicine--it sounds good, but how often is it really practiced? Not as often as it could be, it seems. The most recent evidence of these came this week, when researchers concluded that angioplasties and stents are used far more often than they should be. The problem is, doctors are understandably reluctant to deny patients treatments they think will work, even if …
Get more stents coverage at:
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





